menu
    • menu

    Company profile for Adial Pharmaceuticals

    NEW Drugs in Dev: 7
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder “AUD” using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serio...
    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder “AUD” using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Adial PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1001 Research Park Blvd, Ste 100 Charlottesville, VA 22911
    Telephone
    Telephone
    (434) 422-9800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.adial.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/adial-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AdialPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Adial Pharmaceuticals Acquires Azora, Up to $64M Financing
    Adial Pharmaceuticals Acquires Azora, Up to $64M Financing

    11 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/11/3310671/0/en/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-and-up-to-64-million-financing.html

    GLOBENEWSWIRE
    11 Jun 2026
    Share Share
    Adial Pharma Reveals Q1 2026 Financials & Business Update
    Adial Pharma Reveals Q1 2026 Financials & Business Update

    11 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/11/3291899/26135/en/adial-pharmaceuticals-reports-2026-first-quarter-financial-results-and-provides-business-update.html

    GLOBENEWSWIRE
    11 May 2026
    Share Share
    Adial Pharma Secures U.S. Patent for IP Exclusivity to 2045
    Adial Pharma Secures U.S. Patent for IP Exclusivity to 2045

    29 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7247747

    FIRSTWORD PHARMA
    29 Apr 2026
    Share Share
    Adial Pharma Seeks FDA (CNPV) Pilot Program For AD04 Development
    Adial Pharma Seeks FDA (CNPV) Pilot Program For AD04 Development

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3281641/26135/en/adial-pharmaceuticals-submits-application-to-fda-commissioner-s-national-priority-voucher-cnpv-pilot-program-for-ad04-clinical-development-program.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    Adial Completes Demo Batch for AD04 Phase 3 Trial
    Adial Completes Demo Batch for AD04 Phase 3 Trial

    22 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/22/3279087/26135/en/adial-pharmaceuticals-successfully-completes-manufacturing-of-demonstration-batch-production-enabling-clinical-and-registration-production-for-ad04-planned-phase-3-trial.html

    GLOBENEWSWIRE
    22 Apr 2026
    Share Share
    Adial Pharma Applauds Congress For Bipartisan Bill Enhancing AUD
    Adial Pharma Applauds Congress For Bipartisan Bill Enhancing AUD

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261372/26135/en/Adial-Pharmaceuticals-Commends-Congress-on-Introduction-of-Bipartisan-Legislation-Expanding-Access-to-Emerging-AUD-Therapies-for-Veterans.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search